Cellares closed a $257 million Series D to accelerate commercial roll‑out of its automated cell therapy manufacturing services and to prep for a planned 2027 IPO. The funding will expand global operations, support commercial service launches, and scale the company’s robot‑based manufacturing suites designed to lower cost and standardize autologous and allogeneic cell production. Cellares said proceeds will fund facility expansion, regulatory readiness, and product service deployments aimed at biotechs and CDMOs. The company is positioning its integrated automation to address bottlenecks in cell therapy capacity and aims to convert near‑term contracts into recurring revenue ahead of its public listing.